SG11201507040VA - Predicting response to egfr inhibitors - Google Patents

Predicting response to egfr inhibitors

Info

Publication number
SG11201507040VA
SG11201507040VA SG11201507040VA SG11201507040VA SG11201507040VA SG 11201507040V A SG11201507040V A SG 11201507040VA SG 11201507040V A SG11201507040V A SG 11201507040VA SG 11201507040V A SG11201507040V A SG 11201507040VA SG 11201507040V A SG11201507040V A SG 11201507040VA
Authority
SG
Singapore
Prior art keywords
egfr inhibitors
predicting response
predicting
response
egfr
Prior art date
Application number
SG11201507040VA
Other languages
English (en)
Inventor
Geraldine Strasser
Bryan Lo
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11201507040VA publication Critical patent/SG11201507040VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201507040VA 2013-03-14 2014-03-12 Predicting response to egfr inhibitors SG11201507040VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361781187P 2013-03-14 2013-03-14
PCT/US2014/024544 WO2014159638A1 (en) 2013-03-14 2014-03-12 Predicting response to egfr inhibitors

Publications (1)

Publication Number Publication Date
SG11201507040VA true SG11201507040VA (en) 2015-10-29

Family

ID=50733298

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201507040VA SG11201507040VA (en) 2013-03-14 2014-03-12 Predicting response to egfr inhibitors

Country Status (13)

Country Link
US (1) US20140314747A1 (zh)
EP (1) EP2971108A1 (zh)
JP (1) JP2016513969A (zh)
KR (1) KR20150130422A (zh)
CN (1) CN105074006A (zh)
AU (1) AU2014244593A1 (zh)
BR (1) BR112015022273A2 (zh)
CA (1) CA2902913A1 (zh)
HK (1) HK1211626A1 (zh)
IL (1) IL240468A0 (zh)
MX (1) MX2015012424A (zh)
SG (1) SG11201507040VA (zh)
WO (1) WO2014159638A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130080871A (ko) * 2009-03-20 2013-07-15 제넨테크, 인크. 이중특이적 항-her 항체
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2569520C (en) * 2004-06-04 2023-03-14 Genentech, Inc. Kras mutations for identifying colorectal tumors responsive to cetuximab or panitumumab
AR073679A1 (es) * 2008-09-26 2010-11-24 Takeda Pharmaceutical Prevencion y tratamiento de cancer con la no expresion de lkb1 supresion o mutacion, composicion farmaceutica. usos
EP2507392A4 (en) * 2009-11-30 2013-06-05 Merck Sharp & Dohme METHOD OF IDENTIFYING AND TREATING PATIENTS SENSITIVE TO ANTI-IGF-1R INHIBITION THERAPY

Also Published As

Publication number Publication date
IL240468A0 (en) 2015-09-24
EP2971108A1 (en) 2016-01-20
CA2902913A1 (en) 2014-10-02
BR112015022273A2 (pt) 2017-10-10
WO2014159638A1 (en) 2014-10-02
US20140314747A1 (en) 2014-10-23
CN105074006A (zh) 2015-11-18
MX2015012424A (es) 2016-01-12
HK1211626A1 (zh) 2016-05-27
JP2016513969A (ja) 2016-05-19
AU2014244593A1 (en) 2015-08-27
KR20150130422A (ko) 2015-11-23

Similar Documents

Publication Publication Date Title
HRP20181129T1 (hr) Pirimidin inhibitori fgfr4
HRP20190373T1 (hr) Inhibitori dnk-pk
PL3057959T3 (pl) Inhibitory DNA-PK
AR095266A1 (es) Inhibidores de bromodominios tetraciclicos
SG10201707548RA (en) Method for predicting sensitivity to egfr inhibitor
HK1216531A1 (zh) 新的抑制劑
HK1224288A1 (zh) 作為類糜蛋白酶抑制劑的取代的尿嘧啶
HK1222339A1 (zh) 金屬-β-內酰胺酶的抑制劑
HK1211626A1 (zh) 預測對 抑制劑的響應
GB201313664D0 (en) Bcl-3 inhibitors
GB201305503D0 (en) Inhibitor